References
- Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J. Clin. Oncol.15, 3121–3128 (1997).
- Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res.9, 2940–2949 (2003).
- Walker MD, Green SB, Byar DP et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med.303, 1323–1329 (1980).
- Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer71, 2585–2597 (1993).
- Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol.23(4), 360–364 (1988)
- Newlands ES, Stevens MF, Wedge SR et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev.23, 35–61 (1997)
- Stupp R, Hegi ME, van den Bent MJ et al. Changing paradigms – an update on the multidisciplinary management of malignant glioma. Oncologist11(2), 165–180 (2006)
- Soffietti R, Rudà R, Trevisan E. New chemotherapy options for the treatment of malignant gliomas. Anticancer Drugs18(6), 621–632 (2007).
- Mutter N, Stupp R. Temozolomide: a milestone in neuro-onoclogy and beyond? Expert Rev. Anticancer Ther.6(8), 1187–1204 (2006).
- Prados MD, Scott C, Curran WJ Jr et al. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.J. Clin. Oncol.17, 3389–3395 (1999).
- Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council Trial.J. Clin. Oncol.19, 509–518 (2001).
- Stewart LA. Chemotherapy in adult high grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet359, 1011–1018 (2002).
- Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12, 259–266 (2001).
- Yung WKA, Albright RE, Olson J et al. A Phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83, 588–593 (2000).
- van den Bent M, Hegi M, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer42(5), 582–588 (2006).
- Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
- Wedge SR, Porteous JK, Glaser MG et al.In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs8, 92–97 (1997).
- Van Rijn J, Heimans JJ, Van den Berg J, Van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and x-rays. Int. J. Radiat. Oncol. Biol. Phys.47, 779–784 (2000).
- Brock CS, Newlands ES, Wedge SR et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res.58, 4363–4367 (1998).
- Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.J. Clin. Oncol.20, 1375–1382 (2002).
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol.6, 937–944 (2005)
- Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA293, 557–564 (2005).
- Chamberlain MC, Glantz MJ, Chalmers L et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J. Neurooncol.82(1), 81–83 (2007).
- Hau P, Koch D, Hundsberger T et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology68(9), 688–690 (2007).
- Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J. Clin. Oncol.16, 3851–3857 (1998).
- Gilbert MR, Friedman HS, Kuttesch JF et al. A Phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncology4, 261–267 (2002).
- Brada M, Ashley S, Dowe A et al. Neoadjuvant Phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann. Oncol.16, 942–949 (2005).
- Chinot OL, Barrié M, Fuentes S et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.J. Clin. Oncol.25(12), 1470–1475 (2007).
- Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res. Rev.35, 161–204 (2001).
- Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.J. Clin. Oncol.23, 2411–2422 (2005).
- Bredel M, Bredel C, Juric D et al. Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas.J. Clin. Oncol.24, 274–287 (2006).
- Jaeckle KA, Eyre HJ, Townsend JJ et al. Correlation of tumor O6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.J. Clin. Oncol.16, 3310–3315 (1998).
- Esteller M, Hamilton SR, Burger PC et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res.59, 793–797 (1999).
- Esteller M, Corn PG, Baylin SB et al. A gene hypermethylation profile of human cancer. Cancer Res.61, 3225–3229 (2001).
- Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343, 1350–1354 (2000).
- Balana C, Ramirez JL, Taron M et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin. Cancer Res.9, 1461–1468 (2003).
- Kamiryo T, Tada K, Shiraishi S et al. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)- 3-nitrosourea-based chemotherapy. Neurosurgery54, 349–357 (2004).
- Paz MF, Yaya-Tur R, Rojas-Marcos I et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res.10, 4933–4938 (2004).
- Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res.10, 1871–1874 (2004).
- Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.35, 997–1003 (2005).
- Eoli M, Menghi F, Bruzzone MG et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin. Cancer Res.13, 2606–2613 (2007).
- Stupp R, Hegi M. Methylguanine methyltransferase testing in glioblastoma: when and how? J. Clin. Oncol.25(12), 1459–1460 (2007).
- Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis17, 2329–2336 (1996).
- Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res.56, 5375–5379 (1996).
- Taverna P, Liu L, Hanson AJ et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol.46, 507–516 (2000).
- Lee SM, Thatcher N, Crowther D et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer69, 452–456 (1994).
- Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer88, 1004–1011 (2003)
- Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit. Rev. Oncol. Hematol.53, 241–252 (2005).
- Wick W, Steinbach JP, Kuker WM et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology62, 2113–2115 (2004).
- Tosoni A, Cavallo G, Ermani M et al. Is protracted low-dose temozolomide feasible in glioma patients? Neurology66, 427–429 (2006).
- Franceschi E, Omuro AM, Lassman AB et al. Salvage temozolomide for prior temozolomide responders. Cancer104, 2473–2476 (2005).
- Quinn JA, Pluda J, Dolan ME et al. Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol.20, 2277–2283 (2002).
- Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res.12, 328–331 (2006).
- Tentori L, Leonetti C, Scarsella M et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res.9, 5370–5379 (2003).
- Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl Cancer Inst.96, 56–67, (2004).
- Plummer R, Evans J, Steven N et al. First and final report of a Phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Presented at: 42nd Annual Meeting American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
- Gander M, Leyvraz S, Decosterd L et al. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann. Oncol.10, 831–838 (1999).
- Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol.20, 2388–2399 (2002).
- Plowman J, Waud WR, Koutsoukos AD et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)- 1-nitrosourea. Cancer Res.54, 3793–3799 (1994).
- Hammond LA, Eckardt JR, Kuhn JG et al. A randomized Phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin. Cancer Res.10, 1645–1656 (2004).
- Chang SM, Prados MD, Yung WK et al. Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer100, 1712–1716 (2004).
- Prados MD, Yung WK, Fine HA et al. Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neuro-oncology6, 33–37 (2004).
- Barrié M, Couprie C, Dufour H et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann. Oncol.16, 1177–1184 (2005).
- Herrlinger U, Rieger J, Koch D et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J. Clin. Oncol.24, 4412–4417 (2006).
- Boiardi A, Silvani A, Ciusani E et al. Fotemustine combined with procarbazine in recurrent malignant gliomas: a Phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. J. Neurooncol.52, 149–156 (2001).
- Brandes AA, Turazzi S, Basso U et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology58, 1759–1764 (2002).
- Silvani A, Eoli M, Salmaggi A et al. Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J. Neurooncol.66, 203–208 (2004).
- Grossman SA, Wharam M, Sheidler V et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J. Clin. Oncol.15, 2596–2603 (1997).
- Grossman SA, O’Neill A, Grunnet M et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J. Clin. Oncol.21, 1485–1491 (2003).
- Hare CB, Elion GB, Houghton PJ et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]- 1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol.39, 187–191 (1997).
- Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol.17, 1516–1525 (1999).
- Buckner JC, Reid JM, Wright K et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer97, 2352–2358 (2003).
- Raymond E, Fabbro M, Boige V et al. Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol.14, 603–614 (2003).
- Batchelor TT, Gilbert MR, Supko JG et al. Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97–11. Neuro-oncology6, 21–27 (2004).
- Castellino RC, Elion GB, Keir ST et al. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemother. Pharmacol.45, 345–349 (2000).
- Reardon DA, Quinn JA, Rich JN et al. Phase II trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-oncology6, 134–144 (2004).
- Patel VJ, Elion GB, Houghton PJ et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin. Cancer Res.6, 4154–4157 (2000).
- Reardon DA, Quinn JA, Rich JN et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer104, 1478–1486 (2005).
- Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev. Anticancer Ther.7, 641–661 (2007).
- Sathornsumetee S, Reardon DA, Desjardins A et al. Molecularly targeted therapy for malignant glioma. Cancer110, 13–24 (2007).
- Chakravarti A, Dicker A, Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. J. Radiat. Oncol. Biol. Phys.58, 927–931 (2004).
- Pelloski CE, Ballman KV, Furth AF et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.J. Clin. Oncol.25, 2288–2294 (2007).
- Uhm JH, Ballman KV, Giannini C et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Lieberman FS, Cloughesy T, Fine H et al. NABTC Phase I–II study of ZD1839 for recurrent malignant gliomas and unresectable meningiomas. Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma.J. Clin. Oncol.22, 133–142 (2004).
- Vogelbaum MA, Peereboom D, Stevens G et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Raizer JJ, Abrey LE, Wen P et al. A Phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
- Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
- Prados MD, Lamborn KR, Chang S et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology8, 67–78 (2006).
- Eller JL, Longo SL, Kyle MM et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery56, 155–162 (2005).
- Sadones J, Chaskis E, Joosens EJ et al. A stratified Phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: preliminary results. Presented at: 42nd Annual Meeting American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
- Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16, 1702–1708 (2005).
- Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.J. Clin. Oncol.23, 9359–9368 (2005).
- Vredenburgh JJ, Desjardins A, Herndon JE II et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13(4), 1253–1259 (2007).
- Pope WB, Lai A, Nghiemphu P et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology66(8), 1258–1260 (2006).
- Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA99, 11393–11398 (2002).
- Conrad C, Friedman HS, Reardon DA et al. A Phase I/II trial of single agent PTK 787/ZK 222584, a novel, oral angiogenesis inhibitor in patients with recurrent glioblastoma multiforme (GBM). Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Reardon D, Friedman H, Yung WKA. A Phase I/II of PTK 787/KZ 222584, a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Presented at: 40th Annual Meeting American Society of Clinical Oncology. New Orleans, LA, USA, 5–8 June 2004.
- Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
- Batchelor TT, Sorensen AG, Ankukiewicz N et al. A Phase II trial of AZD (cediranib), an oral, pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Presented at: 43rd Annual Meeting American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
- Bello L, Francolini M, Marthiyn P et al. α(v)β3 and α(v)β5 integrin expression in glioma periphery. Neurosurgery49, 380–390 (2001).
- Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol.25(13), 1637–1638 (2007)
- Nabors LB, Mikkelsen T, Rosenfield SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol.26(13), 1651–1657 (2007).
- Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. Presented at: 43rd Annual Meeting American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
- Fine HA, Kim L, Royce C et al. Results from Phase II trial of enzastaurin in patients with recurrent high grade gliomas. Presented at: 41st Annual Meeting American Society of Clinical Oncology. Orlando, FL, USA, 13–17 May 2005.
- Cloughesy TF, Wen PY, Robins HI et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.J. Clin. Oncol.24, 3651–3656 (2006).
- Gilbert MR, Gaupp P, Lin V et al. A Phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarasar, SCH66336) in recurrent glioblastoma. Presented at: 42nd Annual Meeting American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
- Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs23, 357–361 (2005).
- Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.J. Clin. Oncol.23, 5294–5304 (2005).
- Reardon DA, Rich J, Friedman HS et al. Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol.24, 1253–1265 (2006).
- Doherty L, Gigas D, Kesari S et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology67, 156–158 (2006).
- Galanis E, Jaeckle K, Maurer M et al. N04TB NCCTG Phase II trial of vorinostat in recurrent glioblastoma multiforme. Presented at: 43rd Annual Meeting American Society of Clinical Oncology. Chicago, IL, USA, 1–5 June 2007.
- Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene24, 344–354 (2005).
- Phuphanich S, Supko J, Carson KA et al. Phase I trial of bortezomib in adults with recurrent malignant glioma. Presented at: 42nd Annual Meeting American Society of Clinical Oncology. Atlanta, GA, USA, 2–6 June 2006.
- Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet345, 1008–1012 (1995).
- Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology5, 79–88 (2003).
- Westphal M, Ram Z, Riddle V et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien)148(3), 269–275 (2006).
- La Rocca RV, Vitaz TW, Morassutti DJ et al. A Phase II study of radiation with concomitant and sequential temozolomide in patients with newly diagnosis of malignant glioma (MG) who have undergone surgery with carmustine (BCNU) wafer insertion. Presented at: 41st Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
- Park N, Golden G, Meldorf M et al. PROLONG (prospective look at outcomes nationally with GLIADEL): interim report of malignant glioma experience. Presented at: 35th Annual Meeting American Association of Neurological Surgeons. New Orleans, LA, USA, 15–18 April 2004.
- Kleinberg LR, Weingart J, Burger P et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest.22, 1–9 (2004).
- Olivi A, Grossman SA, Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.J. Clin. Oncol.21, 1845–1849 (2003).
- Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J. Neurooncol.83(1), 97–109 (2007).
- Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Eng. J. Med.356(15), 1527–1535 (2007).
- Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.J. Clin. Oncol.22(9), 1583–1588 (2004).
- Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer97, 657–662 (2007).
- Glantz M, Chamberlain M, Liu Q et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer97, 2262–2266 (2203).
- Chinot OL, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Cancer100(10), 2208–2214 (2004).
- Yung WKA, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.J. Clin. Oncol.17, 2762–2771 (1999).
- Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.J. Clin. Oncol.12(10), 2013–2021 (1994).
- Soffietti R, Rudà R, Bradac GB et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery43(5), 1066–1073 (1998).
- van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology51(4), 1140–1145 (1998).
- Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90(19), 1473–1479 (1998).
- van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol.21(13), 2525–2528 (2003).
- Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin. Pharmacother.5(2), 295–306 (2004).
- Triebels VH, Taphoorn MJ, Brandes A et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology63, 904–906 (2004).
- Cairncross G, Seiferheld W, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.J. Clin. Oncol.24, 2707–2714 (2006).
- van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organization for Research and Treatment of Cancer Phase III Trial. J. Clin. Oncol.24, 2715–2722 (2006).
- Abrey L, Childs B, Paleologos N et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro-oncology8, 183–188 (2006).
- Dehais C, Laigle-Donadey F, Marie Y et al. Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer107, 1891–1897 (2006).
- Sanson M, Cartalat-Carel S, Taillibert S et al. Initial chemotherapy in gliomatosis cerebri. Neurology63(2), 270–275 (2004).
- Levin N, Gomori JM, Siegal T. Chemotherapy as initial treatment in gliomatosi cerebri: results with temozolomide. Neurology63, 354–356 (2004).
- Rudà R, Laguzzi E, Pace A et al. Temozolomide in gliomatosis cerebri: a multi-center retrospective study of the AINO (Italian Association for Neuro-Oncology). Presentend at: 59th Annual Meeting American Academy of Neurology. Boston, MA, USA, 28 April–5 May 2007.